Mounjaro®
Starting from £179.99/mo
Start journey Learn moreTaking Mounjaro while on ramipril is not automatically ruled out, and many people with high blood pressure are prescribed both. Ramipril is an ACE inhibitor used to manage hypertension; Mounjaro (tirzepatide) is a prescription-only weight-loss and diabetes medicine. The key consideration is that as Mounjaro produces weight loss, your blood pressure often falls too, which may mean your ramipril dose needs reviewing by your prescriber. These are prescription-only medicines and any combination requires clinical assessment — your prescriber is the right person to weigh up your individual picture before any change is made.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
There is no established pharmacokinetic interaction between tirzepatide and ramipril, meaning one does not alter how the other is absorbed, distributed or cleared. Mounjaro works on GIP and GLP-1 receptors involved in appetite regulation and blood-sugar control; ramipril works on the renin-angiotensin system to relax blood vessels. Their mechanisms sit on separate pathways.
That said, "no direct drug interaction" does not mean the two medicines can be ignored in combination. The clinical concern is indirect. Mounjaro produces meaningful weight loss in most people who respond to it, and losing 10–20% of body weight has a measurable blood-pressure-lowering effect of its own. If your ramipril dose was calibrated to your pre-treatment blood pressure, it may become a higher dose than you need once treatment is established. The result can be symptomatic low blood pressure (dizziness on standing, light-headedness, fatigue) which is worth flagging to your prescriber rather than dismissing as a Mounjaro side effect.
You can read more about tirzepatide's mechanism and licensed uses on the tirzepatide overview page, and if you want a detailed look at whether you can take Mounjaro with ramipril, that page covers the combination in full. The NHS tirzepatide medicine page covers common cautions in plain language.
This is the practical question our prescribers hear most often from people who are also taking antihypertensives. Gastrointestinal side effects (nausea, loose stools, vomiting) are the most commonly reported effects when starting Mounjaro or moving up through the dose schedule. They are usually mild and settle within a couple of weeks, but while they persist, fluid loss is real.
For someone on ramipril, dehydration matters more than it would otherwise. ACE inhibitors reduce the kidney's ability to compensate for low circulating volume; combined with a drop in blood pressure from weight loss, the result can be pre-renal impairment, the kidneys temporarily underperform because not enough blood is reaching them. Symptoms include reduced urination, unusual thirst, and a feeling of weakness beyond ordinary nausea.
The practical step is straightforward: sip water consistently through the day, especially in the first few weeks of treatment or after a dose increase. Keep your ramipril in the same place you always have (next to the kitchen tap, say) so the routine stays intact even when appetite is low. If you develop persistent vomiting or cannot keep fluids down for more than a day, that warrants a call to your GP or prescriber rather than a wait-and-see approach.
For a broader picture of what else to monitor alongside Mounjaro, the what to take while on Mounjaro page covers compatible medicines and supplements in more detail.
Possibly, over time, though not immediately and not automatically. The blood-pressure benefit from weight loss accumulates gradually over weeks and months rather than appearing after one pen. For most people, their prescriber will want to check blood pressure readings at reviews (typically at the 3-month and 6-month mark) rather than adjusting ramipril pre-emptively.
If home monitoring shows readings consistently lower than your target range (or if you are experiencing dizziness when standing up), that is a clear prompt to contact your prescriber. It is worth knowing that some people reach a point where their cardiovascular risk factors improve enough that their antihypertensive dose can be reduced or, occasionally, withdrawn, that is not a side effect of Mounjaro but a consequence of the underlying condition improving.
Hypertension is one of the weight-related comorbidities that can make someone eligible for Mounjaro under its UK licence, so your prescriber will already be thinking about how your blood pressure picture interacts with treatment. The Mounjaro treatment page explains the eligibility criteria in full. For context on the private cost of treatment, the Mounjaro price comparison page lays out what the UK private market looks like.
Before starting Mounjaro, your prescriber needs a complete medicines list. Ramipril should be on it, alongside any other antihypertensives, diuretics or medicines affecting kidney function. This is standard practice at a registered UK pharmacy: a clinical review is not a checkbox exercise, and at nume a GPhC-registered prescriber personally reads every consultation response before anything is approved.
After starting, the things worth tracking are blood pressure readings (a home monitor is useful), any dizziness especially when moving from sitting or lying to standing, and fluid intake during periods of nausea. If you are also considering other formulations of tirzepatide, our Peptide Sciences tirzepatide page explains what that product is and how it compares. The MHRA's Yellow Card scheme is the right route for reporting unexpected effects with either medicine.
If any of this raises questions about your specific situation, speaking to a prescriber directly is more useful than further reading. You can start a free consultation and a named clinician will review your circumstances the same day.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.